Citations

Showing 10 of 108094 citations.

Commentary: Interictal High Gamma Oscillation Regularity as a Marker for Presurgical Epileptogenic Zone Localization
Kerezoudis, Panagiotis , Kokkinos, Vasileios

Mayo Clinic

Operative Neurosurgery | July 12, 2022 | Volume: 23 | Issue: 2 | Pages: e114-e116

10.1227/ons.0000000000000254 | PMID 35838462 Get It

Incidence of Brain Metastasis as First Event in Patients with Esophageal Carcinoma: A Report from Three Prospective Alliance Clinical Trials
Smith, Ron S., Foster, Nathan R. , Jatoi, Aminah , Thomé, Stephan D. , Miller, Robert C.

Mayo Clinic

No container title available | July 12, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-1815992/v1 Get It

Abstract PurposeHistorically, reported incidence of brain metastasis secondary to esophageal carcinoma is low. We sought to determine the incidence of brain metastasis in a contemporary cohort of patients with carcinoma of the esophagus.MethodsData from patients with localized esophageal carcinoma prospectively enrolled on three curative intent Alliance treatment trials (N0044, N0342, N044E) were reviewed including time to diagnosis of first progression event (brain versus other site) and overall survival.ResultsEighty-five patients comprised the cohort of which 85% were male and 86% had adenocarcinoma primary tumor histology. Thirty-nine of the 85 patients had documented progression to any site, and of those, brain metastasis occurred as the first event in 15% (6 of 39). Adenocarcinoma was the primary histology in all 6 patients and tumor grade was high (3 or 4) in 5 of the 6 patients (one not documented). Median time to brain metastasis (9.6 months) versus non-brain metastasis (12.4 months) and median survival after first progression (5.4 months versus 8.1 months, respectively) were not statistically different.ConclusionIn this prospective cohort of patients with esophageal carcinoma, those with high grade adenocarcinoma appear to have a higher incidence of brain metastasis than historically reported. The pattern of brain metastases corroborates recent findings in terms of incidence, predominance of adenocarcinoma primary tumor histology, timing after diagnosis, and overall survival. Further study to confirm these findings, as well as the value of baseline, restaging and follow-up cranial imaging for brain metastasis is recommended.ClinicalTrials.gov Identifiers: NCT00022139 (NCCTG N0044); NCT00100945 (NCCTG N0342), and NCT00100945 (NCCTG N044E)
Faecal immunochemical testing (FIT) in patients with signs or symptoms of suspected colorectal cancer (CRC): a joint guideline from the Association of Coloproctology of Great Britain and Ireland (ACPGBI) and the British Society of Gastroenterology (BSG)
Monahan, Kevin , Davies, Michael , Abulafi, Muti , Banerjea, Ayan , Nicholson, Brian D , Arasaradnam, Ramesh , Barker, Neil, Booth, Richard F. , Burling, David , Carten, Rachel , Kleijnen, Jos , Machesney, Michael , Pettman, Maria, Pipe, Jenny, Saker, L., Sharp, Linda , Stephenson, James A. , Steele, R. , Monahan, Kevin J , D'Souza, Nigel , East, James E , Sharp, Linda , Steele, Robert Jc , Benton, Sally C. , Booth, Richard, East, James E.

Mayo Clinic

Gut | July 12, 2022 | Volume: 71 | Issue: 10 | Pages: 1939-1962

10.1136/gutjnl-2022-327985 | PMID 35820780 Get It

Faecal immunochemical testing (FIT) has a high sensitivity for the detection of colorectal cancer (CRC). In a symptomatic population FIT may identify those patients who require colorectal investigation with the highest priority. FIT offers considerable advantages over the use of symptoms alone, as an objective measure of risk with a vastly superior positive predictive value for CRC, while conversely identifying a truly low risk cohort of patients. The aim of this guideline was to provide a clear strategy for the use of FIT in the diagnostic pathway of people with signs or symptoms of a suspected diagnosis of CRC. The guideline was jointly developed by the Association of Coloproctology of Great Britain and Ireland/British Society of Gastroenterology, specifically by a 21-member multidisciplinary guideline development group (GDG). A systematic review of 13 535 publications was undertaken to develop 23 evidence and expert opinion-based recommendations for the triage of people with symptoms of a suspected CRC diagnosis in primary care. In order to achieve consensus among a broad group of key stakeholders, we completed an extended Delphi of the GDG, and also 61 other individuals across the UK and Ireland, including by members of the public, charities and primary and secondary care. Seventeen research recommendations were also prioritised to inform clinical management.
Acinetobacter baumannii Genomic Sequence-Based Core Genome Multilocus Sequence Typing Using Ridom SeqSphere+ and Antimicrobial Susceptibility Prediction in ARESdb
Fida, Madiha , Beisken, Stephan , Posch, Andreas E. , Jeraldo, Patricio , Zinsmaster, Nicole M., Patel, Robin , Jeraldo, Patricio R , Murphy, Matthew P., Patel, Robin , Fida, Madiha , Cunningham, Scott A. , Chia, Nicholas , Murphy, Matthew P.

Mayo Clinic

Journal of Clinical Microbiology | July 12, 2022 | Volume: 60 | Issue: 8 | Pages: No page available

10.1128/jcm.00533-22 | PMID 35862760 Get It

Whole-genome sequencing (WGS) is rapidly replacing traditional typing methods for the investigation of infectious disease outbreaks. Additionally, WGS data are being used to predict phenotypic antimicrobial susceptibility. Acinetobacter baumannii , which is often multidrug-resistant, is a significant culprit in outbreaks in health care settings.
The utility of postoperative systemic antibiotic prophylaxis following cardiovascular implantable electronic device implantation: A systematic review and meta‐analysis
Chesdachai, Supavit , DeSimone, Daniel C. , Go, John R, Hassett, Leslie C. , DeSimone, Daniel C , Chesdachai, Supavit , Go, John Raymond , Baddour, Larry M.

Mayo Clinic

Pacing and Clinical Electrophysiology | July 12, 2022 | Volume: 45 | Issue: 8 | Pages: 940-949

10.1111/pace.14561 | PMID 35819103 Get It

AbstractBackgroundThere is insufficient evidence regarding postoperative systemic antibiotic prophylaxis use for more than 24 h following cardiovascular implantable electronic devices (CIED) implantation and its impact on infection prevention. However, this strategy remains a common practice in many institutions.MethodsWe conducted a systematic review and meta‐analysis including studies that compared the outcomes of patients: (1) who received preoperative plus 24 h or more of postoperative antibiotic prophylaxis (intervention group); and (2) who received either preoperative only or preoperative plus less than 24 h of antibiotic prophylaxis (control group). Risk of bias was assessed with ROBINS‐I and ROB‐2 tools. Risk ratio (RR) was pooled using random‐effect meta‐analyses with inverse variance method.ResultsEight studies that included two randomized controlled trials (RCTs) and six cohort studies with a total of 26,187 patients were included in the analysis. Overall, there were no differences in outcomes between the two groups, which included rates of CIED infection (RR 0.77, 95% CI 0.42, 1.42), mortality (RR 1.19, 95% CI 0.69, 2.06), pocket hematoma (RR 1.15, 95% CI 0.44, 3.00) or reintervention (RR 0.87, 95% CI 0.22, 3.46). Of note, the results were primarily impacted by the larger RCT.ConclusionsThere was no benefit of postoperative antibiotic prophylaxis for more than 24 h following CIED implantation in the current systematic review and meta‐analysis. This supports the practice advocated by current guidelines which foster antibiotic stewardship and may result in reductions of adverse drug events, selection for antibiotic resistance, and financial costs of prolonged postoperative antibiotic prophylaxis.
Intracranial Aneurysms in Loeys–Dietz Syndrome: A Multicenter Propensity-Matched Analysis
Perez‐Vega, Carlos , Tripathi, Shashwat , Santos, Jaime L. Martínez , Rahme, Rudy J. , Miller, David A. , Brinjikji, Waleed , Quiñones‐Hinojosa, Alfredo , Meyer, Fredric B. , Fox, W Christopher , Domingo, Ricardo A. , Ramos‐Fresnedo, Andres , Freeman, William D. , Sandhu, Sukhwinder J.S. , Bendok, Bernard R. , Tawk, Rabih G.

Mayo Clinic

Neurosurgery | July 12, 2022 | Volume: 91 | Issue: 4 | Pages: 541-546

10.1227/neu.0000000000002070 | PMID 35876667 Get It

BACKGROUND: Loeys–Dietz syndrome (LDS) is an autosomal dominant connective tissue disorder characterized by a classic triad of hypertelorism, bifid uvula and/or cleft palate, and generalized arterial tortuosity. There are limited data on the prevalence and rupture risk of intracranial aneurysms (IAs) in the setting of LDS, with no established guidelines. OBJECTIVE: To analyze the prevalence and rupture risk of IA in LDS. METHODS: Electronic medical records of patients with a confirmed diagnosis of LDS and available cerebrovascular imaging were reviewed. Patients were divided into 2 groups based on the presence of IA. Unmatched and propensity-matched analyses were used to identify potential risk factors for aneurysm formation. RESULTS: Records of 1111 patients were screened yielding a total of 60 patients with a diagnosis of LDS. Eighteen (30%) patients had IA, 4 (22.2%) of whom had multiple aneurysms for a total of 24 IAs. Twenty-three (95.8%) aneurysms were located in the anterior circulation; none of them were ruptured. On unmatched analysis, age ( P = .015), smoking history ( P = .034), hypertension ( P = .035), and number of extracranial aneurysms ( P < .001) were significantly higher in patients with IA. After matching for age, sex, race, stroke history, family history, and extracranial aneurysms, smoking history ( P = .009) remained significant. CONCLUSION: Patients with LDS have an increased risk of IAs, especially with a history of smoking. The prevalence rate of IAs in our series was 30%. Screening imaging should be considered at diagnosis, and patients should be encouraged to abstain from smoking. Further studies are needed to elucidate the risk of IA rupture and treatment considerations in this unique population.
Geometric structure guided model and algorithms for complete deconvolution of gene expression data
Chen, Duan, Li, Shaoyu , Wang, Xue

Mayo Clinic

Foundations of Data Science | July 12, 2022 | Volume: 4 | Issue: 3 | Pages: 441

10.3934/fods.2022013 | PMID 38250319 Get It

<p style='text-indent:20px;'>Complete deconvolution analysis for bulk RNA-seq data is important and helpful to distinguish whether the differences of disease-associated GEPs (gene expression profiles) in tissues of patients and normal controls are due to changes in cellular composition of tissue samples, or due to GEPs changes in specific cells. One of the major techniques to perform complete deconvolution is nonnegative matrix factorization (NMF), which also has a wide-range of applications in the machine learning community. However, the NMF is a well-known strongly ill-posed problem, so a direct application of NMF to RNA-seq data will suffer severe difficulties in the interpretability of solutions. In this paper, we develop an NMF-based mathematical model and corresponding computational algorithms to improve the solution identifiability of deconvoluting bulk RNA-seq data. In our approach, we combine the biological concept of marker genes with the solvability conditions of the NMF theories, and develop a geometric structures guided optimization model. In this strategy, the geometric structure of bulk tissue data is first explored by the spectral clustering technique. Then, the identified information of marker genes is integrated as solvability constraints, while the overall correlation graph is used as manifold regularization. Both synthetic and biological data are used to validate the proposed model and algorithms, from which solution interpretability and accuracy are significantly improved.</p>
FIGO statement: Disparities in patients' access to benign gynecological surgery
Villegas‐Echeverri, Juan Diego , Ganyaglo, Gabriel , Aklilu, Fekade Ayenachew, Wasson, Megan , Ganyaglo, Gabriel Y K , Wasson, Megan

Mayo Clinic

International Journal of Gynecology & Obstetrics | July 12, 2022 | Volume: 158 | Issue: 3 | Pages: 499-501

10.1002/ijgo.14323 | PMID 35819011 Get It

Acacetin, a Potent Transient Outward Current Blocker, May Be a Novel Therapeutic for KCND3 -Encoded Kv4.3 Gain-of-Function-Associated J-Wave Syndromes
Ye, Dan , Zhou, Wei , Hamrick, Samantha K. , Tester, David J. , Kim, C.S. John, Barajas-Martínez, Héctor , Hu, Dan , Giudicessi, John R. , Antzelevitch, Charles , Ackerman, Michael J. , Kim, C.S. John, Ye, Dan

Mayo Clinic

Circulation: Genomic and Precision Medicine | July 12, 2022 | Volume: 15 | Issue: 5 | Pages: No page available

10.1161/circgen.120.003238 | PMID 35861988 Get It

Background: The transient outward current (Ito) that mediates early (phase 1) repolarization is conducted by the KCND3 -encoded Kv4.3 pore-forming α-subunit. KCND3 gain-of-function mutations have been reported previously as a pathogenic substrate for J wave syndromes (JWS), including the Brugada syndrome and early repolarization syndrome, as well as autopsy-negative sudden unexplained death (SUD). Acacetin, a natural flavone, is a potent Ito current blocker. Acacetin may be a novel therapeutic for KCND3 -mediated J wave syndrome. Methods: KCND3-V392I was identified in an 18-year-old male with J wave syndrome/early repolarization syndrome, and a history of cardiac arrest including ventricular tachycardia/ventricular fibrillation and atrial fibrillation/atrial flutter. Pathogenic KCND3 mutation was engineered by site-directed mutagenesis and co-expressed with wild-type KChIP2 in TSA201 cells. Gene-edited/variant-corrected isogenic control and patient-specific pluripotent stem cell–derived cardiomyocytes (iPSC-CMs) from the p. Val392Ile-KCND3-positive patient were generated. I to currents and action potentials were recorded before and after treatment with Acacetin using the whole cell patch-clamp and multielectrode array technique. Western blot and immunocytochemistry were performed to investigate KCND3 expression. Results: KCND3-V392I demonstrated a marked gain-of-function phenotype, increasing peak I to current density by 92.2% ( P <0.05 versus KCND3-WT). KCND3 expression was significantly increased in KCND3-V392I-derived iPSC-CMs ( P <0.05 versus isogenic control). While KCND3-WT revealed an IC50 of 7.2±1.0 µmol/L for acacetin effect, 30 µmol/L acacetin dramatically inhibited KCND3-V392I peak Ito current density by 96.2% ( P <0.05 versus before Acacetin). Ito was also increased by 60.9% in Kv4.3-V392I iPSC-CM ( P <0.05 versus isogenic control iPSC-CM). Ten micromoles per liter acacetin, a concentration approaching its IC50 value, inhibited Ito by ≈50% in patient-derived iPSC-CMs and reduced the accentuated action potential notch displayed in KCND3-V392I-derived iPSC-CMs. Conclusions: This preclinical study provides pharmacological and functional evidence to suggest that Acacetin may be a novel therapeutic for patients with KCND3 gain-of-function-associated J wave syndrome by inhibiting I to and abolishing the accentuated action potential notch in patient-derived iPSC-CMs.
Comprehensive characterization of antral and pyloric contractions by high resolution manometry: applied physiology in suspected gastroparesis
Zheng, Ting , BouSaba, Joelle, Sannaa, Wassel , Eckert, Deborah J., Burton, Duane D. , Camilleri, Michael

Mayo Clinic

American Journal of Physiology-Gastrointestinal and Liver Physiology | July 12, 2022 | Volume: 323 | Issue: 3 | Pages: G255-G264

10.1152/ajpgi.00119.2022 | PMID 35819155 Get It

Current selection of different treatments for patients with gastroparesis is empiric or based on trial and error, though pyloric distensibility and diameter may predict response to pyloric interventions. High-resolution antropyloroduodenal manometry (HR-ADM) can characterize a variety of postprandial antral contractile and pyloric motility dysfunctions in patients with suspected gastroparesis. HR-ADM shows promise to provide guidance for selection and individualization of treatments such as prokinetic agents or pyloric interventions for patients with gastroparesis based on documented pathophysiology.